Literature DB >> 2078551

Regulation of expression of human immunodeficiency virus.

G N Pavlakis1, B K Felber.   

Abstract

Human immunodeficiency virus (HIV), the causative agent of acquired immune deficiency syndrome (AIDS), encodes regulatory factors necessary for its expression. The study of these factors clearly indicates the importance and complexity of post-trascriptional processes in regulating gene expression. Two regulatory proteins, Tat and Rev, are necessary for viral replication. These small nuclear proteins accumulate primarily in the nucleoli and act on HIV via sequence-specific elements found on the viral RNA. Both the Tat responsive element (TAR) and the Rev responsive element (RRE) map within regions of strong RNA secondary structure. While all viral mRNAs contain TAR, only the mRNAs producing HIV structural proteins contain RRE. Tat increases the levels of all viral mRNAs. Its function is complex and involves transcriptional and possibly post-transcriptional steps. Rev promotes the transport of viral mRNAs containing RRE from the nucleus to the cytoplasm and increases the half-life of these viral mRNAs. A third factor, Nef, is a cytoplasmic myristylated protein that has been proposed to down-regulate virus expression. These factors are integrated in a feedback regulatory network that dictates the balanced expression of viral components. The study of HIV expression in human cells will advance our understanding of the mechanisms related to the pathogenicity of HIV. This knowledge may also lead to novel diagnostic and therapeutic approaches to combat AIDS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2078551

Source DB:  PubMed          Journal:  New Biol        ISSN: 1043-4674


  61 in total

Review 1.  Translational control of viral gene expression in eukaryotes.

Authors:  M Gale; S L Tan; M G Katze
Journal:  Microbiol Mol Biol Rev       Date:  2000-06       Impact factor: 11.056

2.  Human immunodeficiency virus type 1 Rev activation can be achieved without Rev-responsive element RNA if Rev is directed to the target as a Rev/MS2 fusion protein which tethers the MS2 operator RNA.

Authors:  S Venkatesan; S M Gerstberger; H Park; S M Holland; Y Nam
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

3.  Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression.

Authors:  S Schwartz; M Campbell; G Nasioulas; J Harrison; B K Felber; G N Pavlakis
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

4.  Different sites of interaction for Rev, Tev, and Rex proteins within the Rev-responsive element of human immunodeficiency virus type 1.

Authors:  L Solomin; B K Felber; G N Pavlakis
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

5.  Linker-scanning mutational analysis of the transcriptional activity of the human immunodeficiency virus type 1 long terminal repeat.

Authors:  S L Zeichner; J Y Kim; J C Alwine
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

6.  Rapid activation and subsequent down-regulation of the human immunodeficiency virus type 1 promoter in the presence of Tat: possible mechanisms contributing to latency.

Authors:  C M Drysdale; G N Pavlakis
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

7.  Phylogenetic and physical analysis of the 5' leader RNA sequences of avian retroviruses.

Authors:  P B Hackett; M W Dalton; D P Johnson; R B Petersen
Journal:  Nucleic Acids Res       Date:  1991-12-25       Impact factor: 16.971

Review 8.  Translation-targeted therapeutics for viral diseases.

Authors:  J B Harford
Journal:  Gene Expr       Date:  1995

9.  Expression of a human immunodeficiency virus type 1 long terminal repeat/simian virus 40 early region fusion gene in transgenic mice.

Authors:  J Skowronski
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

10.  The Rev protein of human immunodeficiency virus type 1 promotes polysomal association and translation of gag/pol and vpu/env mRNAs.

Authors:  D M D'Agostino; B K Felber; J E Harrison; G N Pavlakis
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.